MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

MDT

97.56

-1.22%↓

148.57

+2%↑

VEEV

239.64

-0.58%↓

HQY

94.29

-4.24%↓

PHR.US

17.17

+1.72%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

513.79 -7.49

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

509.12

Max

556.51

Belangrijke statistieken
By Trading Economics
Inkomsten	-72M -114M
Verkoop	74M 287M
Winstmarge	-39.75
Werknemers	528
EBITDA	-68M -106M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+12.58% upside

Dividenden
By Dow Jones
Volgende Winsten	25 feb 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	4.2B 13B
Vorige openingsprijs	521.28
Vorige sluitingsprijs	513.79

Nieuwssentiment

By Acuity

50%

187 / 370 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

9 jan 2026, 22:18 UTC

Marktinformatie

Changes Needed for Exxon Mobil to Return to Venezuela -- Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jan 2026, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

9 jan 2026, 21:43 UTC

Winsten

Acquisities, Fusies, Overnames

These Stocks Moved the Most Today: Oklo, Vistra, Opendoor, Intel, GM, Revolution Medicines, Tilray, and More -- Barrons.com

9 jan 2026, 20:39 UTC

Marktinformatie

GE Vernova Seen With Rising Concern of Overcapacity -- Market Talk

9 jan 2026, 20:38 UTC

Marktinformatie

U.S. Natural Gas Falls on Loose Supply Outlook -- Market Talk

9 jan 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Cathie Wood's ARK Invest Takes a New Stake in Broadcom -- and Sold Another Hot Stock -- Barrons.com

9 jan 2026, 20:30 UTC

Marktinformatie

Oil Makes Weekly Gains in Geopolitically Driven Trade -- Market Talk

9 jan 2026, 20:15 UTC

Marktinformatie

Chevron Seen With Modest Opportunity to Boost Venezuela Oil Production -- Market Talk

9 jan 2026, 20:07 UTC

Marktinformatie

Global Equities Roundup: Market Talk

9 jan 2026, 20:07 UTC

Marktinformatie

Goldman Sachs' Pivot from Consumer Lending Seen as Positive -- Market Talk

9 jan 2026, 19:58 UTC

Acquisities, Fusies, Overnames

Merck in Talks to Buy Revolution Medicines for Around $30 Billion -- WSJ

9 jan 2026, 19:42 UTC

Marktinformatie

Adobe Seen With Weak Competitive Position Compared to Rivals -- Market Talk

9 jan 2026, 19:38 UTC

Acquisities, Fusies, Overnames

Wolters Kluwer Acquires StandardFusion >WTKWY

9 jan 2026, 19:31 UTC

Winsten

Qualcomm Stock Falls After Downgrade. The Apple Supplier Has an iPhone Problem. -- Barrons.com

9 jan 2026, 19:28 UTC

Winsten

Apple Stock Set to Break Brutal Losing Streak. Why It Remains Evercore's 'Top Pick.' -- Barrons.com

9 jan 2026, 18:30 UTC

Marktinformatie

U.S. Oil Rig Count Falls by 3 to 409 -- Market Talk

9 jan 2026, 18:23 UTC

Marktinformatie

Reports of Canada Oil Sector's Demise Are Premature -- Market Talk

9 jan 2026, 17:20 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Basic Materials Roundup: Market Talk

9 jan 2026, 17:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

9 jan 2026, 17:19 UTC

Marktinformatie

Energy Prices Not Seen Supporting More Drilling -- Market Talk

9 jan 2026, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

9 jan 2026, 17:07 UTC

Marktinformatie

McDonald's Promotions Appear Successful -- Market Talk

9 jan 2026, 17:06 UTC

Marktinformatie

Oil Futures on Track for Weekly Gains -- Market Talk

9 jan 2026, 17:05 UTC

Winsten

Stocks Sail Past Jobs Data, Tariff Opinion Delay. Earnings Season Looms. -- Barrons.com

9 jan 2026, 16:57 UTC

Marktinformatie

Energy Activity Tumbles in 4Q, KC Fed Survey Finds -- Market Talk

9 jan 2026, 16:46 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

9 jan 2026, 16:46 UTC

Marktinformatie

Dollar Could Stay Steady For Now, More Likely to Fall Than Rise -- Market Talk

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

12.58% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 626.22 USD 12.58%

Hoogste 900 USD

Laagste 527 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Gebaseerd op 12 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

187 / 370 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.